The primary objective of this study is to determine the accuracy of the technical performance of a newly developed non-invasive, continuous PPG-based BP algorithm by comparing absolute one-minute values of systolic (SBP) and diastolic (DBP) BP with…
ID
Source
Brief title
Condition
- Other condition
- Cardiac disorders, signs and symptoms NEC
- Respiratory tract therapeutic procedures
Synonym
Health condition
Respiratoire aandoeningen
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The primary endpoint of the study is the technical performance verification of
a PPG-based algorithm for continuous one-minute SBP and DBP values derived from
viQtor data, meeting standards set by the Association for the Advancement of
Medical Instrumentation (AAMI). This is deemed acceptable for clinical purposes
if the mean absolute error (MAE) <= 5 mmHg and the standard deviation (SD) of
the difference <= 8 mmHg between simultaneously paired measurements from viQtor
SQ-RD and the arterial line (White et al., 1993).
Secondary outcome
8.1.2 Secondary study parameters/endpoints
• Evaluate whether viQtor*s BP data adheres to at least Grade B of the BHS
standard.
o For clinical acceptability (minimum Grade B), the MEA and distribution of the
MAE between simultaneously paired measurements of both DBP and SBP between the
viQtor SQ-RD and the arterial line adhere to the following criteria.
Additionally, it is essential that at least 20% of these one-minute median BP
measurements obtained by the viQtor SQ-RD are available:
* <= 5 mmHg for 60% of the paired measurements (Grade A);
* <= 10 mmHg for 85% of the paired measurements (Grade A);
* <= 15 mmHg for 95% of the paired measurements (Grade A);
* <= 5 mmHg for 50% of the paired measurements (Grade B);
* <=10 mmHg for 75% of the paired measurements (Grade B);
* <=15 mmHg for 90% of the paired measurements (Grade B).
• Evaluate whether viQtor*s BP measurements meet the accuracy requirements of
the 81060-2:2022 standard (ISO, 2018).
o For clinical acceptability, the MEA and SD between simultaneously paired
systolic and diastolic BP measurements must adhere to the following criteria
set by the 81060-2:2022 standard: Acceptable for clinical purposes if the MAE
is <= 5 mmHg and the SD is <= 8 mmHg between simultaneously paired measurements
from viQtor SQ-RD and the arterial line (ISO, 2018).
• Descriptive, MAE and SD between simultaneously paired measurements of mean
arterial pressure (MAP) from viQtor SQ-RD and the arterial line.
o Acceptable for clinical purposes if MAE < 6 mmHg and SD is < 10 mmHg between
simultaneously paired measurements from viQtor SQ-RD and the arterial line.
• Descriptive, ARMS between paired one-minute median values of DBP and SBP
values estimated using a 2-point model-based method (using ear PPG and viQtor
PPG) and invasive arterial line, in accordance with the AAMI standards (White
et al., 1993).
o Acceptable for clinical purposes if the MAE <= 5 mmHg and the SD of the
difference between the estimated DBP and SBP values of the model and the
arterial line is <= 8 mmHg (White et al., 1993).
• Comparison of ARMS and other relevant statistical outcomes between viQtor
SQ-RD and the invasive arterial line, and between the 2-point model-based
method and invasive arterial line.
• Descriptive, ARMS between simultaneously paired measurements of SpO2 from
viQtor SQ-RD and ear SpO2 measurements from the Philips IntelliVue MX750
monitor.
o Acceptable for clinical purposes if the total ARMS is within 2%.
• Descriptive ARMS between simultaneously paired measurements of SpO2 from
viQtor SQ-RD and SaO2 from blood gasses of the arterial line.
o Acceptable for clinical purposes if the total ARMS is within 2%.
• Descriptive, ARMS between simultaneously paired measurements of Heart Rate
(HR) from viQtor SQ-RD and ECG-based of the Philips IntelliVue MX750 monitor.
o Acceptable for clinical purposes if the total ARMS is within +/- 3 beats/min.
• Descriptive, ARMS between simultaneously paired measurements of Respiratory
Rate (RR) from viQtor SQ-RD and Capnography of the Philips IntelliVue MX750
monitor.
o Acceptable for clinical purposes if the total ARMS is within +/- 3
breaths/min.
• Descriptive, ARMS between simultaneously paired measurements of MAP, DBP and
SBP values from the viQtor SQ-RD and the cuff-based sphygmomanometers.
o Acceptable for clinical purposes if the MAE <= 5 mmHg and the SD of the
difference is <= 8 mmHg between the simultaneously paired measurements from
viQtor SQ-RD and the cuff-based measurements (White et al., 1993).
• Evaluate the correlation and the ability for prediction of treatment related
complications with the absolute measurements and trends from the various
non-invasive measured parameters with the viQtor SQ-RD and the occurrence.
Background summary
This study, supported by EFRO (European Regional Development Fund), responds to
the limitations of conventional blood pressure (BP) measurement methods, like
cuff-based sphygmomanometers and invasive arterial catheterization. Effective
blood pressure (BP) management is vital for maintaining cardiovascular health
and detecting potential health issues early. Traditional BP monitoring methods,
including cuff-based sphygmomanometers and invasive arterial lines, are widely
used but come with significant limitations. Photoplethysmography (PPG)
technology emerges as a promising alternative, providing a cost-effective,
continuous, and non-invasive solution for BP monitoring. smartQare B.V.*s
developed viQtor wearable, which uses PPG technology, provides a novel approach
aimed at addressing these challenges associated with current BP measurement
methods. This clinical study aims to develop, optimize, and technically verify
the performance of a PPG-based BP algorithm within the viQtor. The goal is to
develop a user-friendly, accurate, and durable wearable device, suitable for
widespread use in both hospitals and outpatient care settings, thereby
enhancing patient care and reducing healthcare personnel burden.
Study objective
The primary objective of this study is to determine the accuracy of the
technical performance of a newly developed non-invasive, continuous PPG-based
BP algorithm by comparing absolute one-minute values of systolic (SBP) and
diastolic (DBP) BP with the continuous invasive arterial DBP and SBP data. The
study*s objective adheres to standards set by the Advancement of Medical
Instrumentation (AAMI) standards (White et al., 1993).
Study design
The study is a prospective data-collection study, with a primary focus on the
development, optimization, and technical performance verification of a new
PPG-based algorithm for continuous BP measurements within the viQtor device. It
involves the continuous collection of raw PPG data and vital signs, such as BP,
heart rate (HR), respiratory rate (RR), and blood oxygen saturation (SpO2),
from a total of 55 perioperative ICU patients at Catharina Hospital Eindhoven
(CZE). Data collection periods will vary for each patient, ranging from 30
minutes to 48 hours. This study gathers raw PPG and BP data from 55 ICU
patients using the viQtor research device (viQtor SQ-RD), the Ear Pulse
Oximeter, and an invasive arterial line. Subsequently, these raw data will be
used to develop, optimize, and technically verify the performance of the BP
algorithm by applying machine learning techniques and manual features by the
research team.
Study burden and risks
The data protocol employed in this study does not interfere with the standard
clinical care provided to perioperative ICU patients with an invasive arterial
line, ensuring it runs concurrently without adding any extra burden. A total of
55 participating patients will wear the viQtor SQ-RD on their upper arm for a
duration ranging from a minimum of 30 minutes to a maximum of 48 hours. Since
continuous monitoring of BP, HR, RR, and SpO2 is part of standard care, the
additional gathering of PPG data via the viQtor SQ-RD introduces minimal risk.
The device*s strategic placement on the upper arm, especially in sterile
environments like operating rooms, avoids stringent sterility protocols by
being positioned under the operating table drape, thereby reducing infection
risks. The potential of skin reaction or irritation from extended wear is
acknowledged, presenting a slight risk. Overall, this study is designed to
ensure minimal risk and burden to the participating patients.
Kapteynstraat 1
Noordwijk 2201BB
NL
Kapteynstraat 1
Noordwijk 2201BB
NL
Listed location countries
Age
Inclusion criteria
To be eligible to participate in this study, a subject must meet the following
criteria:
- must be 18 years or older.
- must be admitted to the ICU at the Catharina Hospital Eindhoven
postoperatively.
- must have a clinical indication for continuous BP measurement with an
arterial line.
- must be willing and able to provide informed consent.
Exclusion criteria
A potential subject who meets any of the following criteria will be excluded
from this study:
- Patients with known extremely sensitive skin or allergies to metal or
plastics.
- Patients with significant deformities, swelling, irritation, injuries,
degenerative changes, infectious diseases, or edema on the upper arm where the
device's PPG sensor will be placed. If these conditions affect only one arm, it
is recommended to wear the device on the healthy arm.
- Patients with tremors and/or convulsions (e.g. Parkinson).
- Patients with tattoos on the upper arms where the device's PPG sensor will be
placed. If tattoos are present on only one arm, wearing the device on the arm
without tattoos is recommended.
- Patients with upper arm sizes outside the wearable's fitting range.
- Emergency (surgical) patients, as obtaining true informed consent may not be
feasible.
Design
Recruitment
Medical products/devices used
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
CCMO | NL86036.000.24 |